The primary goals of this study are to evaluate whether TNFR2 is expressed on melanoma, to determine which TNFR mediates TNF- mediated resistance reprogramming to MAPK inhibitors (MAPKi) and to decipher whether INB03, a dominant-negative TNF biologic and specific antagonist of solTNF, can antagonize this therapeutic resistance pathway. The gene discussed is TNF; the disease is melanoma.